Sharon Nofech-Mozes

Dr. Sharon Nofech-Mozes


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JLJoema Felipe Lima
Joema Felipe Lima
SNSharon Nofech-Mozes
Sharon Nofech-Mozes
JBJane Bayani
Jane Bayani
JBJohn M. S. Bartlett
John M. S. Bartlett
The epithelial to mesenchymal transition (EMT) is a cellular program that is involved in embryonic development; wound healing, but also in tumorigenesis. Breast carcinoma (BC) is the most common cancer in women worldwide, and the majority of deaths (90%) are caused by invasion and metastasis. The EMT plays an important role in invasion and subsequent metastasis. Several distinct biological events integrate a cascade that leads not only to a change from an epithelial to mesenchymal phenotype, but allows for detachment, migration, invasion and ultimately, colonization of a second site. Understanding the biological intricacies of the EMT may provide important insights that lead to the development of therapeutic targets in pre-invasive and invasive breast cancer, and could be used as biomarkers identifying tumor subsets with greater chances of recurrence, metastasis and therapeutic resistance leading to death.

1 September 2008 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
SNSharon Nofech-Mozes
Sharon Nofech-Mozes
MKMahmoud A Khalifa
Mahmoud A Khalifa
NINadia Ismiil
Nadia Ismiil
RSReda S Saad
Reda S Saad
WHWedad M Hanna
Wedad M Hanna
ZGZeina Ghorab
Zeina Ghorab

8 May 2021 in Journal of Medical Imaging
Verified
Journal Article
Open access
PDF file
NPNicholas A. Petrick
Nicholas A. Petrick
SAShazia Akbar
Shazia Akbar
KCKenny H. Cha
Kenny H. Cha
SNSharon Nofech-Mozes
Sharon Nofech-Mozes
BSBerkman Sahiner
Berkman Sahiner
FGfor the BreastPathQ Challenge Group
for the BreastPathQ Challenge Group
Neoadjuvant treatment (NAT) of breast cancer is the administration of therapeutic agents before surgery; it is a treatment option often used for patients with locally advanced breast disease1 and more recently is an acceptable option for operable breast cancer of certain molecular subtypes. The administration of NAT can reduce tumor size, allowing patients to become candidates for limited surgical resection or breast-conserving surgery rather than mastectomy.1 In addition to affecting parameters, such as histologic architecture, nuclear features, and proliferation,2 response to NAT may reduce tumor cellularity (TC), defined as the percentage area of the overall tumor bed comprising tumor cells from invasive or in situ carcinoma:3

1 May 2012 in Applied Immunohistochemistry & Molecular Morphology
Verified
Journal Article
Closed access
SNSharon Nofech-Mozes
Sharon Nofech-Mozes
EVEmily T. Vella
Emily T. Vella
SDSukhbinder Dhesy-Thind
Sukhbinder Dhesy-Thind
KHKaren L. Hagerty
Karen L. Hagerty
PMPamela B. Mangu
Pamela B. Mangu
WHWedad M. Hanna
Wedad M. Hanna
Assessment of hormone receptors (estrogen and progesterone) helps to direct therapy for women with breast cancer. Immunohistochemistry is most commonly used to assess hormone receptor status and it is essential that these tests are performed accurately and reliably within and across laboratories. The overall purpose of this guideline is to improve the quality and accuracy of hormone receptor testing and its utility as a prognostic and predictive marker for invasive and in situ breast cancer. Medline, EMBASE, the Cochrane Database of Systematic Reviews, and abstracts from the San Antonio Breast Cancer Symposium were searched. An environmental scan of the internet and of international guideline developers and key organizations was performed. Preanalytic elements such as the collection, fixation, and storage of samples, and analytic elements such as selection of antibodies and scoring methods that seem to offer the best results for immunohistochemical assessment of hormone receptors are presented. Proficiency testing or quality assurance of immunohistochemistry is described.

16 January 2018 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
DBDina Bassiouny
Dina Bassiouny
NINadia Ismiil
Nadia Ismiil
VDValerie Dubé
Valerie Dubé
GHGuangming Han
Guangming Han
MCMatthew Cesari
Matthew Cesari
SNSharon Nofech-Mozes
Sharon Nofech-Mozes
The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.

10 July 2015 in SpringerPlus
Verified
Journal Article
Open access
PDF file
JKJonathan Klein
Jonathan Klein
IKIwa Kong
Iwa Kong
Lawrence Frank PaszatLawrence Frank Paszat
Lawrence Frank Paszat
SNSharon Nofech-Mozes
Sharon Nofech-Mozes
WHWedad Hanna
Wedad Hanna
EREileen Rakovitch
Eileen Rakovitch
Mastectomy is effective treatment for ductal carcinoma in situ (DCIS) but some women will develop chest wall recurrence. Most chest wall recurrences that develop after mastectomy are invasive cancer and are associated with poorer prognosis. Past studies have been unable to identify factors predictive of chest wall recurrence. Therefore, it remains unclear if a subset exists of women with DCIS treated by mastectomy experience a high rate of recurrence in whom more aggressive treatment may be of benefit. We report outcomes of all women in Ontario (N = 1,546) diagnosed with pure DCIS from 1994 to 2003 treated with mastectomy without radiotherapy and evaluate factors associated with the development of chest wall recurrence. Treatments and outcomes were validated by chart review. Proportional differences were compared using Chi square analyses. Survival analyses were used to study the development of chest wall recurrence in relation to patient and tumor characteristics. Median follow-up was 10.1 years. Median age was 57.1 years. 36 patients (2.3%) developed chest wall recurrence. The 10-year actuarial chest wall recurrence-free survival rates and invasive chest wall recurrence-free survival rates were 97.6 and 98.6%, respectively. There was no difference in cumulative 10 year rates of chest wall recurrence by age at diagnosis (50 years = 2.1%; p = 0.19), nuclear grade (high = 3.0%, intermediate = 1.4%, low = 1.0%, unreported = 2.5%; p = 0.41), or among women with close or positive resection margins (positive = 3.0%, 2 mm or less = 1.4%, >2 mm = 1.5%, unreported = 2.8%; p = 0.51). On univariate and multivariable analysis, none of the factors were significantly associated with the development of chest wall recurrence. In this population cohort, individuals treated by mastectomy experienced low rates of chest wall recurrence. We did not identify a subset of patients with a high rate of chest wall recurrence, including those with positive margins.